RE:RE:Valuation Potential...updatedCorrect on delays.... however... think about what you are saying...
...the process for CV Antibody has been slowed by, ironically, of all things, Covid-19! However it would appear that the FDA is still stuck on vaccines, therapuetics, CRRTs, ventilators, and testing (do you have CV? and testing accuracy ). Any intelligent reading on what will happen next in this pandemic, leads one to conclude that sooner or later THEY will have to focus their attention on Antibodies....out of necessity. After that, the focus can get back to other non-CV19 medical drugs/devices, etc. My feeling is that the FDA is so overwhelmed with treatments, vaccines, etc. that they are falling behind on what will be the next phase (booster delivery when the benfits of vaccines reduce over time)
However, that does not mean that investors shouldn't concern themselves with valuation (subject to approval). If an asset is mispriced - it's worthy of discussion and revelation.
Are delayed cancer treatment Trials and reviews, etc. causing drug companies to lose 3/4 of their value due to FDA re-prioritizations and Covid delays?
Is long term revenue potential for every non-Covid related medical stock now somehow irrelevent?
SQI at least offers a potentially valuable solution to the future delivery of scarce resources (e.g. medical triaging diagnostics, identification of those most at risk due to falling antibody levels, etc.)
Sadly the market just does not know it yet.
That is a choice made by Mgt. IMO...though the logic for not drawing attention to themselves, escapes me at the moment. Before releasing a movie, you begin marketing at least a year in advance of the release date of the film (its called teaser trailers)
While you are correct that we do not know the odds of approval, nor do we know the timing...that should not preclude investors from trying to value their investment, or suggest that it may be mispriced in relation to it's potential value to the world...or to suggest that it is under-appreciated by the investment community !
I can show you thousands of stocks that produced multi-bag shareholder returns years in advance of them getting approval from the FDA and or generating a dime in revenue. We have been delayed - that is obvious. But for how long? Certainly not years. They are still saying an FDA EU ruling on Covid Antibody testing by Q3 2021 - which by my calcuation ends in about 7-8 weeks time. Will it be delayed again? Perhaps. But I'm allowed to count chickens and sheep as I take an interim nap.
Regarding the thousands of stock that DO anticipate future earnings...I'll mention just one. Theranos. The fake blood diagnostic company from 10 + years ago. It undeservedly reached a valuation of $ 9B USD. And that was without the benefit of claiming that they could address an out of control pandemic that has now killed millions. Not suggesting that SQI hype something that is not real. Just that they serve notice that they POTENTIALLY have a VERY valuable tool in the burgeoning world of diagnostics. Capital is attracted to the potential for breakthroughs. In particular medical breakthroughs. And it's attracted via promotion and marketing. Some win and some lose, but the system works.
Sorry...if I own a stock that I believe that it is wildly underappreciated....then I will count my chickens under a variety of scenarios (good and bad)...until the cows come home. ..all while my fingers are crossed that the owners an Mgt agree to let the horses out of the barn...so that I can eat filet mignon like a pig while awaiting whatever necessary period of time for commercialization to take place.
MM